On March 19, 2025, Opus Genetics amended its bylaws to enhance stockholder rights, including allowing 20% of shareholders to call special meetings and reducing the threshold for removing directors to a simple majority. Additionally, on March 14, 2025, the company filed a patent infringement complaint against Sandoz for attempting to produce a generic version of RYZUMVI.